The pre-requisite of a second-generation glioma PET biomarker

Journal of the Neurological Sciences

Volumn 298, Issue 1-2, 2010, Pages 11-16

  Borbely, Katalin ^a   Wintermark, Max ^b   Martos, Janos ^c   Fedorcsak, Imre ^c   Bognar, Laszlo ^d   Kasler, Miklos ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^b UNIVERSITY OF VIRGINIA   (United States)

^c NATIONAL INSTITUTE OF NEUROSURGERY   (Hungary)

^d UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Biomarker; Glioma; PET

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; ACETIC ACID; ACETIC ACID C 11; ACETIC ACID DERIVATIVE; AMINO ACID; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CARBON 11; CHOLINE; CHOLINE C 11; CHOLINE DERIVATIVE; CHOLINE F 18; FLUORINE 18; FLUORINE DERIVATIVE; FLUORODEOXYGLUCOSE; GADOLINIUM PENTETATE; LEVODOPA; METHIONINE; METHIONINE C 11; NITROIMIDAZOLE DERIVATIVE; NUCLEOSIDE DERIVATIVE; O (2 FLUOROETHYL)LEVO TYROSINE F 18; O 2 FLUORO LEVO TYROSINE F 18; PHENYLACETIC ACID C 11; RADIOPHARMACEUTICAL AGENT; TEMOZOLOMIDE; THALLIUM 201; TRACER; TYROSINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; CYCLOTRON; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DRUG CLEARANCE; DRUG DESIGN; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; GLIOMA; HUMAN; NEUROIMAGING; NEUROSURGERY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICIAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RADIOCHEMISTRY; REVIEW; SIGNAL NOISE RATIO; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

BIOLOGICAL MARKERS; BRAIN NEOPLASMS; FLUORODEOXYGLUCOSE F18; GLIOMA; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 77958152580     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2010.07.024     Document Type: Review

References (108)

1. C. Halldin, B. Gulyas, and L. Farde PET studies with carbon-11 radioligands in neuropsychological drug development Current Radiopharm Design 2001 1907 1929
2. A. Verbruggen, H.H. Coenen, J.R. Deverre, D. Guilloteau, B. Langstrom, and P.A. Salvadori Guideline to regulations for radiopharmaceuticals in early phase clinical trials in the EU Eur J Nucl Med Mol Imaging Nov;35 11 2008 2144 2151
3. Y. Yamamoto, Y. Nishiyama, N. Kimura, R. Kameyama, N. Kawai, and T. Hatakeyama 11C-acetate PET in the evaluation of brain glioma: comparison with 11C-methionine and 18F-FDG-PET Mol Imaging Biol 10 5 Sep 2008 281 287 Epub 2008 Jun 10
4. O. De Witte, N. Oulad Ben Taib, F. Branle, S. Rorive, J. Brotchi, and S. Goldman Contribution of PET to the management of patients with low-grade glioma Neurochirurgie 50 4 Sep 2004 468 473
5. B. Kaschten, A. Stevenaert, B. Sadzot, M. Deprez, C. Degueldre, and G. Del Fiore Preoperative evaluation of 54 gliomas by PET with fluorine-18- fluorodeoxyglucose and/or carbon-11-methionine J Nucl Med 39 5 1998 May 778 785
6. K. Borbély, I. Nyáry, M. Tóth, K. Ericson, and B. Gulyáset Optimization of semi-quantification in metabolic PET studies with 18F-fluorodeoxyglucose and 11C-methionine in the determination of malignancy of gliomas J Neurol Sci 246 1-2 Jul 15 2006 85 94 Epub 2006 Mar 6
7. C. Pötzi, A. Becherer, C. Marosi, G. Karanikas, M. Szabo, and R. Dudczak [11C]methionine and [18F]fluorodeoxyglucose PET in the follow-up of glioblastoma multiforme J Neurooncol 84 3 Sep 2007 305 314 Epub 2007 May 11
8. T. Kato, J. Shinoda, N. Nakayama, K. Miwa, A. Okumura, and H. Yano Metabolic assessment of gliomas using [11C]-methionine, [18F]- fluorodeoxyglucose, and [11C]-choline positron-emission tomography Am J Neuroradiol. 29 2008 1176 1182
9. S. Yamaguchi, S. Terasaka, H. Kobayashi, T. Shiga, R. Usui, and K. Hirata Indolent dorsal midbrain tumor: new findings based on positron emission tomography J Neurosurg Pediatr 3 4 Apr 2009 270 275
10. B. Gulyás, I. Nyáry, and K. Borbély FDG, MET or CHO? The quest for the optimal PET tracer for glioma imaging continues Nat Clin Pract Neurol 4 9 Sep 2008 470 471 Epub 2008 Jul 15
11. P.K. Kincaid, S.M. El-Saden, S.H. Park, and B.W. Goy Cerebral gangliogliomas: preoperative grading using FDG-PET and 201Tl-SPECT Am J Neuroradiol. 19 1998 801 806
12. M. Gómez-Río, A. Rodríguez-Fernández, C. Ramos-Font, E. López-Ramírez, and J.M. Llamas-Elvira Diagnostic accuracy of 201-Thallium-SPECT and 18F-FDG-PET in the clinical assessment of glioma recurrence Eur J Nucl Med Mol Imaging 35 5 May 2008 966 975 Epub 2008 Jan 3
13. A.G. Vlassenko, B. Thiessen, B.J. Beattie, M.G. Malkin, and R.G. Blasberg Evaluation of early response to SU101 target-based therapy in patients with recurrent supratentorial malignant gliomas using FDG PET and Gd-DTPA MRI J Neurooncol 46 3 2000 249 259
14. Z. Huang, C. Zuo, Y. Guan, Z. Zhang, P. Liu, and F. Xue Misdiagnoses of 11C-choline combined with 18F-FDG PET imaging in brain tumours Nucl Med Commun 29 4 Apr 2008 354 358
15. H.J. Wester, M. Herz, W. Weber, P. Heiss, R. Senekowitsch-Schmidtke, and M. Schwaiger Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-l- tyrosine for tumor imaging J Nucl Med 40 1 Jan 1999 205 212
16. H.E. Wang, S.Y. Wu, C.W. Chang, R.S. Liu, L.C. Hwang, and T.W. Lee Evaluation of F-18-labeled amino acid derivatives and [18F]FDG as PET probes in a brain tumor-bearing animal model Nucl Med Biol 32 4 May 2005 367 375
17. D. Pauleit, G. Stoffels, A. Bachofner, F.W. Floeth, M. Sabel, and H. Herzog Comparison of (18)F-FET and (18)F-FDG PET in brain tumors Nucl Med Biol 36 7 Oct 2009 779 787 Epub 2009 Jul 29
18. D.C. Weber, T. Zilli, F. Buchegger, N. Casanova, G. Haller, and M. Rouzaud (18)F]Fluoroethyltyrosine-positron emission tomography-guided radiotherapy for high-grade glioma Radiat Oncol 24 3 Dec 2008 44
19. H. Vees, S. Senthamizhchelvan, R. Miralbell, D.C. Weber, O. Ratib, and H. Zaidi Assessment of various strategies for 18F-FET PET-guided delineation of target volumes in high-grade glioma patients Eur J Nucl Med Mol Imaging 36 2 Feb 2009 182 193 Epub 2008 Sep 26
20. E.W. Lau, K.J. Drummond, R.E. Ware, E. Drummond, A. Hogg, and G. Ryan Comparative PET study using F-18 FET and F-18 FDG for the evaluation of patients with suspected brain tumour J Clin Neurosci 17 1 Jan 2010 43 49 Epub 2009 Dec 9
21. K.J. Langen, K. Hamacher, M. Weckesser, F. Floeth, G. Stoffels, and D. Bauer O-(2-[18F]fluoroethyl)-l-tyrosine: uptake mechanisms and clinical applications Nucl Med Biol 33 3 Apr 2006 287 294
22. F. Thiele, J. Ehmer, M.D. Piroth, M.J. Eble, H.H. Coenen, and H.J. Kaiser The quantification of dynamic FET PET imaging and correlation with the clinical outcome in patients with glioblastoma Phys Med Biol 54 18 Sep 21 2009 5525 5539 Epub 2009 Aug 28
23. G. Pöpperl, F.W. Kreth, J.H. Mehrkens, J. Herms, K. Seelos, and W. Koch FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading Eur J Nucl Med Mol Imaging 34 12 Dec 2007 1933 1942 Epub 2007 Sep 1
24. F.W. Floeth, D. Pauleit, M. Sabel, G. Reifenberger, G. Stoffels, and W. Stummer 18F-FET PET differentiation of ring-enhancing brain lesions J Nucl Med 47 5 May 2006 776 782
25. N. Spaeth, M.T. Wyss, J. Pahnke, G. Biollaz, A. Lutz, and K. Goepfert Uptake of 18F-fluorocholine, 18F-fluoro-ethyl-l: -tyrosine and 18F-fluoro-2-deoxyglucose in F98 gliomas in the rat Eur J Nucl Med Mol Imaging 33 6 Jun 2006 673 682 Epub 2006 Mar 15
26. T.S. Lee, S.H. Ahn, B.S. Moon, K.S. Chun, J.H. Kang, and G.J. Cheon Comparison of 18F-FDG, 18F-FET and 18F-FLT for differentiation between tumor and inflammation in rats Nucl Med Biol 36 6 Aug 2009 681 686
27. M. Wyss, S. Hofer, M. Bruehlmeier, M. Hefti, C. Uhlmann, and E. Bärtschi Early metabolic responses in temozolomide treated low-grade glioma patients J Neurooncol 95 1 Oct 2009 87 93 Epub 2009 Apr 18
28. M.T. Wyss, N. Spaeth, G. Biollaz, J. Pahnke, P. Alessi, and E. Trachsel Uptake of 18F-Fluorocholine, 18F-FET, and 18F-FDG in C6 gliomas and correlation with 131I-SIP(L19), a marker of angiogenesis J Nucl Med 48 4 Apr 2007 608 614
29. F. Stockhammer, A. von Deimling, M. Synowitz, C. Blechschmidt, and F.K. van Landeghem Expression of glucose transporter 1 is associated with loss of heterozygosity of chromosome 1p in oligodendroglial tumors WHO grade II J Mol Histol 39 5 Oct 2008 553 560 Epub 2008 Aug 26
30. M.D. Piroth, M. Pinkawa, R. Holy, G. Stoffels, C. Demirel, and C. Attieh Integrated-boost IMRT or 3-D-CRT using FET-PET based auto-contoured target volume delineation for glioblastoma multiforme-a dosimetric comparison Radiat Oncol 23 4 Nov 2009 57
31. D.C. Weber, N. Casanova, T. Zilli, F. Buchegger, M. Rouzaud, and P. Nouet Recurrence pattern after [(18)F]fluoroethyltyrosine-positron emission tomography-guided radiotherapy for high-grade glioma: a prospective study Radiother Oncol 93 3 Dec 2009 586 592 Epub 2009 Sep 24
32. A. Stadlbauer, O. Prante, C. Nimsky, E. Salomonowitz, M. Buchfelder, and T. Kuwert Metabolic imaging of cerebral gliomas: spatial correlation of changes in O-(2-18F-fluoroethyl)-l-tyrosine PET and proton magnetic resonance spectroscopic imaging J Nucl Med 49 5 May 2008 721 729 Epub 2008 Apr 15
33. A. Stadlbauer, E. Pölking, O. Prante, C. Nimsky, M. Buchfelder, and T. Kuwert Detection of tumour invasion into the pyramidal tract in glioma patients with sensorimotor deficits by correlation of (18)F-fluoroethyl-l: -tyrosine PET and magnetic resonance diffusion tensor imaging Acta Neurochir (Wien) 151 9 Sep 2009 1061 1069 Epub 2009 May 26
34. W. Rachinger, C. Goetz, G. Pöpperl, F.J. Gildehaus, F.W. Kreth, and M. Holtmannspötter Positron emission tomography with O-(2-[18F]fluoroethyl) -l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas Neurosurgery 57 3 Sep 2005 505 511 discussion 505-11
35. A.M. Messing-Jünger, F.W. Floeth, D. Pauleit, G. Reifenberger, R. Willing, and J. Gärtner Multimodal target point assessment for stereotactic biopsy in children with diffuse bithalamic astrocytomas Childs Nerv Syst 18 8 Aug 2002 445 449 Epub 2002 Jul 26
36. F.W. Floeth, D. Pauleit, H.J. Wittsack, K.J. Langen, G. Reifenberger, and K. Hamacher Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F]fluoroethyl-l-tyrosine and magnetic resonance spectroscopy J Neurosurg 102 2 Feb 2005 318 327
37. F.W. Floeth, M. Sabel, G. Stoffels, D. Pauleit, K. Hamacher, and H.J. Steiger Prognostic value of 18F-fluoroethyl-l-tyrosine PET and MRI in small nonspecific incidental brain lesions J Nucl Med 49 5 May 2008 730 737 Epub 2008 Apr 15
38. F. Stockhammer, M. Misch, P. Horn, A. Koch, N. Fonyuy, and M. Plotkin Association of F18-fluoro-ethyl-tyrosin uptake and 5-aminolevulinic acid-induced fluorescence in gliomas Acta Neurochir (Wien) 151 11 Nov 2009 1377 1383 Epub 2009 Jul 29
39. G. Pöpperl, C. Götz, W. Rachinger, F.J. Gildehaus, J.C. Tonn, and K. Tatsch Value of O-(2-[18F]fluoroethyl)-l-tyrosine PET for the diagnosis of recurrent glioma Eur J Nucl Med Mol Imaging 31 11 Nov 2004 1464 1470 Epub 2004 Jul 10
40. D. Pauleit, F. Floeth, K. Hamacher, M.J. Riemenschneider, G. Reifenberger, and H.W. Müller O-(2-[18F]fluoroethyl)-l-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas Brain 128 Pt 3 Mar 2005 678 687 Epub 2005 Feb 2
41. O.S. Fedorova, O.F. Kuznetsova, S.V. Shatik, M.A. Stepanova, Belokon' IuN, and V.I. Maleev (18)F-labeled tyrosine derivatives: synthesis and experimental studies on accumulation in tumors and abscesses Bioorg Khim 35 3 May-Jun 2009 334 343
42. C. Burchardt, P.J. Riss, F. Zoller, S. Maschauer, O. Prante, and T. Kuwert (68)Ga]Ga-DO(2)A-(OBu-l-tyr)(2): synthesis, (68)Ga-radiolabeling and in vitro studies of a novel (68)Ga-DO(2)A-tyrosine conjugate as potential tumor tracer for PET Bioorg Med Chem Lett 19 13 Jul 1 2009 3498 3501 Epub 2009 May 7
43. D. Pauleit, F. Floeth, L. Tellmann, K. Hamacher, H. Hautzel, and H.W. Müller Comparison of O-(2-18F-fluoroethyl)-l-tyrosine PET and 3-123I-iodo-alpha-methyl-l-tyrosine SPECT in brain tumors J Nucl Med 45 3 Mar 2004 374 381
44. A. van Waarde, D.C. Cobben, A.J. Suurmeijer, B. Maas, W. Vaalburg, and E.F. de Vries Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model J Nucl Med 45 4 Apr 2004 695 700
45. A.H. Jacobs, A. Thomas, L.W. Kracht, H. Li, C. Dittmar, and G. Garlip 18F-fluoro-l-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors J Nucl Med. 46 12 Dec 2005 1948 1958
46. W. Chen, T. Cloughesy, N. Kamdar, N. Satyamurthy, M. Bergsneider, and L. Liau Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG J Nucl Med 46 6 Jun 2005 945 952
47. Y. Yamamoto, T.Z. Wong, T.G. Turkington, T.C. Hawk, D.A. Reardon, and R.E. Coleman 3′-Deoxy-3′-[F-18]fluorothymidine positron emission tomography in patients with recurrent glioblastoma multiforme: comparison with Gd-DTPA enhanced magnetic resonance imaging Mol Imaging Biol 8 6 Nov-Dec 2006 340 347
48. A. Hlobilkova, J. Ehrmann, P. Knizetova, V. Krejci, O. Kalita, and Z. Kolar Analysis of VEGF, Flt-1, Flk-1, nestin and MMP-9 in relation to astrocytoma pathogenesis and progression Neoplasma 56 4 2009 284 290
49. M.S. Bradbury, D. Hambardzumyan, P.B. Zanzonico, J. Schwartz, S. Cai, and E.M. Burnazi Dynamic small-animal PET imaging of tumor proliferation with 3′-deoxy-3′-18F-fluorothymidine in a genetically engineered mouse model of high-grade gliomas J Nucl Med 49 3 Mar 2008 422 429 Epub 2008 Feb 20
50. S.J. Price, T.D. Fryer, M.C. Cleij, A.F. Dean, J. Joseph, and R. Salvador Imaging regional variation of cellular proliferation in gliomas using 3′-deoxy-3′-[18F]fluorothymidine positron-emission tomography: an image-guided biopsy study Clin Radiol 64 1 Jan 2009 52 63 Epub 2008 Sep 4
51. W. Chen, S. Delaloye, D.H. Silverman, C. Geist, J. Czernin, and J. Sayre Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study J Clin Oncol 25 30 Oct 20 2007 4714 4721
52. H. Backes, R. Ullrich, B. Neumaier, L. Kracht, K. Wienhard, and A.H. Jacobs Noninvasive quantification of (18)F-FLT human brain PET for the assessment of tumour proliferation in patients with high-grade glioma Eur J Nucl Med Mol Imaging Aug 12 2009 [Epub ahead of print] PMID: 19672593
53. R.T. Ullrich, L.W. Kracht, and A.H. Jacobs Neuroimaging in patients with gliomas Semin Neurol 28 4 Sep 2008 484 494 Epub 2008 Oct 8
54. L.H. Wei, H. Su, I.J. Hildebrandt, M.E. Phelps, J. Czernin, and W.A. Weber Changes in tumor metabolism as readout for mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma Clin Cancer Res 14 11 Jun 1 2008 3416 3426
55. M. Muzi, A.M. Spence, F. O'Sullivan, D.A. Mankoff, J.M. Wells, and J.R. Grierson Kinetic analysis of 3′-deoxy-3′-18F-fluorothymidine in patients with gliomas J Nucl Med 47 10 Oct 2006 1612 1621
56. A. van Waarde, and P.H. Elsinga Proliferation markers for the differential diagnosis of tumor and inflammation Curr Pharm Des 14 31 2008 3326 3339
57. T. Hatakeyama, N. Kawai, Y. Nishiyama, Y. Yamamoto, Y. Sasakawa, and T. Ichikawa 11C-methionine (MET) and 18F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma Eur J Nucl Med Mol Imaging 35 11 Nov 2008 2009 2017 Epub 2008 Jun 10
58. N. Kawai, M. Kagawa, K. Miyake, Y. Nishiyama, Y. Yamamoto, and H. Shiraishi Use of 11F-fluorothymidine positron emission tomography in brain tumor No Shinkei Geka 37 7 Jul 2009 657 664
59. P.R. Luyten, A.J. Marien, W. Heindel, P.H. van Gerwen, K. Herholz, and J.A. den Hollander Metabolic imaging of patients with intracranial tumors: H-1 MR spectroscopic imaging and PET Radiology 176 3 Sep 1990 791 799
60. J.R. Alger, J.A. Frank, A. Bizzi, M.J. Fulham, B.X. DeSouza, and M.O. Duhaney Metabolism of human gliomas: assessment with H-1 MR spectroscopy and F-18 fluorodeoxyglucose PET Radiology 177 3 Dec 1990 633 641
61. J.H. Anderson, J.D. Strandberg, D.F. Wong, P.S. Conti, P.B. Barker, and S.J. Blackband Multimodality correlative study of canine brain tumors. Proton magnetic resonance spectroscopy, positron emission tomography, and histology Invest Radiol 29 6 Jun 1994 597 605
62. N. Shinoura, M. Nishijima, T. Hara, T. Haisa, H. Yamamoto, and K. Fujii Brain tumors: detection with C-11 choline PET Radiology 202 2 Feb 1997 497 503
63. C. Vanpouille, N. Le Jeune, D. Kryza, A. Clotagatide, M. Janier, and F. Dubois Influence of multidrug resistance on (18)F-FCH cellular uptake in a glioblastoma model Eur J Nucl Med Mol Imaging 36 8 Aug 2009 1256 1264 Epub 2009 Mar 20
64. M. Utriainen, M. Komu, V. Vuorinen, P. Lehikoinen, P. Sonninen, and T. Kurki Evaluation of brain tumor metabolism with [11C]choline PET and 1H-MRS J Neurooncol 62 3 May 2003 329 338
65. A. van Waarde, P.L. Jager, K. Ishiwata, R.A. Dierckx, and P.H. Elsinga Comparison of sigma-ligands and metabolic PET tracers for differentiating tumor from inflammation J Nucl Med 47 1 Jan 2006 150 154
66. T. Hara, N. Kosaka, and H. Kishi PET imaging of prostate cancer using carbon-11-choline J Nucl Med 39 6 Jun 1998 990 995
67. J. Kotzerke, J. Prang, B. Neumaier, B. Volkmer, A. Guhlmann, and K. Kleinschmidt Experience with carbon-11 choline positron emission tomography in prostate carcinoma Eur J Nucl Med 27 9 Sep 2000 1415 1419
68. D. Mathews, and O.K. Oz Positron emission tomography in prostate and renal cell carcinoma Curr Opin Urol 12 5 Sep 2002 381 385
69. K. Bouchelouche, J. Capala, and P. Oehr Positron emission tomography/computed tomography and radioimmunotherapy of prostate cancer Curr Opin Oncol 21 5 Sep 2009 469 474
70. P.A. Jerabek, T.B. Patrick, M.R. Kilbourn, D.D. Dischino, and M.J. Welch Synthesis and biodistribution of 18F-labeled fluoronitroimidazoles: potential in vivo markers of hypoxic tissue Int J Rad Appl Instrum A 37 7 1986 599 605
71. J.S. Rasey, Z. Grunbaum, S. Magee, N.J. Nelson, P.L. Olive, and R.E. Durand Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells Radiat Res 111 2 Aug 1987 292 304
72. J.S. Rasey, W.J. Koh, J.R. Grierson, Z. Grunbaum, and K.A. Krohn Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia Int J Radiat Oncol Biol Phys 17 5 Nov 1989 985 991
73. J.J. Casciari, and J.S. Rasey Determination of the radiobiologically hypoxic fraction in multicellular spheroids from data on the uptake of [3H]fluoromisonidazole Radiat Res 141 1 Jan 1995 28 36
74. P.E. Valk, C.A. Mathis, M.D. Prados, J.C. Gilbert, and T.F. Budinger Hypoxia in human gliomas: demonstration by PET with fluorine-18- fluoromisonidazole J Nucl Med 33 12 Dec 1992 2133 2137
75. J.S. Rasey, J.J. Casciari, P.D. Hofstrand, M. Muzi, M.M. Graham, and L.K. Chin Determining hypoxic fraction in a rat glioma by uptake of radiolabeled fluoromisonidazole Radiat Res 153 2000 84 92
76. H.J. Tochon-Danguy, J.I. Sachinidis, F. Chan, J.G. Chan, C. Hall, and L. Cher Imaging and quantitation of the hypoxic cell fraction of viable tumor in an animal model of intracerebral high-grade glioma using [18F]fluoromisonidazole (FMISO) Nucl Med Biol 29 2 Feb 2002 191 197
77. L.M. Cher, C. Murone, N. Lawrentschuk, S. Ramdave, A. Papenfuss, and A. Hannah Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies J Nucl Med 47 3 Mar 2006 410 418 (Pubitemid 46768482)
78. K.R. Swanson, G. Chakraborty, C.H. Wang, R. Rockne, H.L. Harpold, and M. Muzi Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas J Nucl Med 50 1 Jan 2009 36 44 Epub 2008 Dec 17
79. M.D. Szeto, G. Chakraborty, J. Hadley, R. Rockne, M. Muzi, and E.C. Alvord Jr. Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas Cancer Res 69 10 May 15 2009 4502 4509 Epub 2009 Apr 14
80. A. Huchet, P. Fernandez, M. Allard, Y. Belkacémi, J.P. Maire, and R. Trouette Molecular imaging of tumour hypoxia Cancer Radiothér 13 8 Dec 2009 747 757 Epub 2009 Oct 23
81. A.M. Spence, M. Muzi, K.R. Swanson, F. O'Sullivan, J.K. Rockhill, and J.G. Rajendran Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival Clin Cancer Res 14 9 May 1 2008 2623 2630
82. D.B. Buxton, M. Schwaiger, A. Nguyen, M.E. Phelps, and H.R. Schelbert Radiolabeled acetate as a tracer of myocardial tricarboxylic acid cycle flux Circ Res 63 3 Sep 1988 628 634
83. J.J. Armbrecht, D.B. Buxton, R.C. Brunken, M.E. Phelps, and H.R. Schelbert Regional myocardial oxygen consumption determined noninvasively in humans with [1-11C]acetate and dynamic positron tomography Circulation 80 4 Oct 1989 863 872
84. M.A. Brown, D.W. Myears, and S.R. Bergmann Validity of estimates of myocardial oxidative metabolism with carbon-11 acetate and positron emission tomography despite altered patterns of substrate utilization J Nucl Med 30 2 Feb 1989 187 193
85. C.G. Henes, S.R. Bergmann, M.N. Walsh, B.E. Sobel, and E.M. Geltman Assessment of myocardial oxidative metabolic reserve with positron emission tomography and carbon-11 acetate J Nucl Med 30 9 Sep 1989 1489 1499
86. S.D. Jonson, and M.J. Welch Investigations into tumor accumulation and peroxisome proliferator activated receptor binding by F-18 and C-11 fatty acids Nucl Med Biol 29 2 2002 Feb 211 216
87. P. Shreve, P.C. Chiao, H.D. Humes, M. Schwaiger, and M.D. Gross Carbon-11-acetate PET imaging in renal disease J Nucl Med 36 9 Sep 1995 1595 1601
88. P.D. Shreve, and M.D. Gross Imaging of the pancreas and related diseases with PET carbon-11-acetate J Nucl Med 38 8 Aug 1997 1305 1310
89. N. Oyama, H. Akino, H. Kanamaru, Y. Suzuki, S. Muramoto, and Y. Yonekura 11C-acetate PET imaging of prostate cancer J Nucl Med 43 2 Feb 2002 181 186
90. C.L. Ho, S.C. Yu, and D.W. Yeung 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses J Nucl Med 44 2 Feb 2003 213 221
91. T. Tsuchida, H. Takeuchi, H. Okazawa, T. Tsujikawa, and Y. Fujibayashi Grading of brain glioma with 1-11C-acetate PET: comparison with 18F-FDG PET Nucl Med Biol 35 2 Feb 2008 171 176
92. J. Marik, A. Ogasawara, B. Martin-McNulty, J. Ross, J.E. Flores, and H.S. Gill PET of glial metabolism using 2-18F-fluoroacetate J Nucl Med 50 6 Jun 2009 982 990 Epub 2009 May 14
93. W.D. Heiss, K. Wienhard, R. Wagner, H. Lanfermann, A. Thiel, and K. Herholz F-Dopa as an amino acid tracer to detect brain tumors J Nucl Med 37 7 Jul 1996 1180 1182
94. H. Alheit, L. Oehme, C. Winkler, F. Füchtner, A. Hoepping, and J. Grabowski Radiation treatment planning in brain tumours: potential impact of 3-O-methyl-6-[(18)F]fluoro-l-DOPA and PET Nuklearmedizin 47 5 2008 200 204
95. C.J. Ledezma, W. Chen, V. Sai, B. Freitas, T. Cloughesy, and J. Czernin 18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience Eur J Radiol 71 2 Aug 2009 242 248 Epub 2008 May 29
96. F. Peng, C. Juhasz, K. Bhambhani, D. Wu, D.C. Chugani, and H.T. Chugani Assessment of progression and treatment response of optic pathway glioma with positron emission tomography using alpha-[(11)C]methyl-l-tryptophan Mol Imaging Biol 9 3 May-Jun 2007 106 109
97. O. Schnell, B. Krebs, J. Carlsen, I. Miederer, C. Goetz, and R.H. Goldbrunner Imaging of integrin {alpha}v{beta}3 expression in patients with malignant glioma by [18F]galacto-RGD positron emission tomography Neuro Oncol 11 6 Dec 2009 861 870
98. T. Ogawa, S. Miura, M. Murakami, H. Iida, J. Hatazawa, and A. Inugami Quantitative evaluation of neutral amino acid transport in cerebral gliomas using positron emission tomography and fluorine-18 fluorophenylalanine Eur J Nucl Med 23 8 Aug 1996 889 895
99. A. van Waarde, K. Shiba, J.R. de Jong, K. Ishiwata, R.A. Dierckx, and P.H. Elsinga Rapid reduction of sigma1-receptor binding and 18F-FDG uptake in rat gliomas after in vivo treatment with doxorubicin J Nucl Med 48 8 Aug 2007 1320 1326 Epub 2007 Jul 13
100. W. Cai, K. Chen, K.A. Mohamedali, Q. Cao, S.S. Gambhir, and M.G. Rosenblum PET of vascular endothelial growth factor receptor expression J Nucl Med 47 12 Dec 2006 2048 2056
101. A.R. Hsu, W. Cai, A. Veeravagu, K.A. Mohamedali, K. Chen, and S. Kim Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel J Nucl Med 48 3 Mar 2007 445 454
102. K. Chen, W. Cai, Z.B. Li, H. Wang, and X. Chen Quantitative PET imaging of VEGF receptor expression Mol Imaging Biol 11 1 Jan-Feb 2009 15 22 Epub 2008 Sep 11
103. S.S. Chae, W.S. Kamoun, C.T. Farrar, N.D. Kirkpatrick, E. Niemeyer, and A.M. de Graaf Angiopoietin-2 Interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas Clin Cancer Res 16 14 Jul 15 2010 3618 3627 Epub 2010 May 25
104. I. Velikyan, A.L. Sundberg, O. Lindhe, A.U. Höglund, O. Eriksson, and E. Werner Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors J Nucl Med 46 11 Nov 2005 1881 1888
105. A. Pal, A. Glekas, M. Doubrovin, J. Balatoni, M. Namavari, and T. Beresten Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography Mol Imaging Biol 8 5 Sep-Oct 2006 262 277
106. G. Abourbeh, S. Dissoki, O. Jacobson, A. Litchi, R. Ben Daniel, and D. Laki Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors Nucl Med Biol 34 1 Jan 2007 55 70
107. H. Wang, J.M. Yu, X.R. Song, G.R. Yang, D.B. Mu, and S.Q. Zhao Molecular imaging of epidermal growth factor receptor in glioma-bearing rats Zhonghua Zhong Liu Za Zhi 30 5 May 2008 343 346
108. F.T. Lee, G.J. O'Keefe, H.K. Gan, A.J. Mountain, G.R. Jones, and T.H. Saunder Immuno-PET quantitation of de2-7 epidermal growth factor receptor expression in glioma using 124I-IMP-R4-labeled antibody ch806 J Nucl Med 51 6 Jun 2010 967 972 Epub 2010 May 19